Skip to content

Efficiency of liposomal bupivacaine for postoperative analgesia based on bilateral quadratus lumborum nerve block after cesarean section: a double-blind, randomized controlled trial

Efficiency of liposomal bupivacaine for postoperative analgesia based on bilateral quadratus lumborum nerve block after cesarean section

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095835
Enrollment
Unknown
Registered
2025-01-14
Start date
2025-01-20
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-cesarean pain

Interventions

Liposomal group(LB):Participants in the LB group will receive a bilateral quadratus lumbar nerve block under ultrasound guidance using bupivacaine liposomal injection (20 ml per side, 133 mg).
Ropivacaine + PCIA group(R-P):Participants in the R-P arm will receive a bilateral quadratus lumbar nerve block under ultrasound guidance using ropivacaine injection (20 mL per side, 0.375% ropivacain
PCIA group(P):Participants enrolled in group P will be managed with standard PCIA, without supplementary nerve block interventions.

Sponsors

The Affiliated Hospital of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 18 and above; 2. Elective cesarean section; 3. Fetuses at term, defined as 37 to 42 weeks of gestation; 4. Individuals who provide consent to participate in this study and sign the informed consent document.

Exclusion criteria

Exclusion criteria: 1. Presence of local infection at the proposed injection site; 2. Exhibited contraindications for spinal anesthesia; 3. Known hypersensitivity to trial-related medications; 4. Significant cardiovascular or pulmonary disease; 5. Suffered from severe liver or kidney dysfunction; 6. Having a history of significant mental or other health conditions, including severe visual or auditory impairments, or an inability to communicate, which precludes assessment or examination; 7. Past medical history of neurological deficits; 8. Chronic pain conditions; 9. Current use or abuse of opioids.

Design outcomes

Primary

MeasureTime frame
The visual analogue scale pain score, evaluated during standardized movement;

Secondary

MeasureTime frame
The visual analogue scale pain score at rest;Patient self-assessment of Quality of Recovery-15 (QoR-15) scale;Postoperative acute analgesic requests;Postoperative anxiety assessment of repeat cesarean section;Subjective sleep quality;Nausea;Vomiting;Postoperative sufentanil consumption;Length of hospital stay;Single walking episode duration;Patient’s satisfaction with analgesic;

Countries

China

Contacts

Public ContactWang Yanting

The Affiliated Hospital of Qingdao University

wangyanting1520@qdu.edu.cn+86 186 6180 7709

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026